We "Solved" Ebola. That Illusion Is Now Killing 700 People in Congo.

Looking at the next one to six months — the short-term horizon — I believe this outbreak has not yet reached its peak. The clearest quantitative frame for the stakes comes from CDC MMWR scenario modeling: if the DRC and international partners can push the patient isolation rate from its current approximately 20% to 70%, the probability of exceeding 10,000 cumulative cases within three months drops to just 5%. Maintain the current 20% rate, and the probability of exceeding 20,000 cases in the same window climbs to 65%. That is not a marginal difference — it is a categorical shift in outbreak trajectory, achievable without a vaccine or therapeutic, through operational improvements alone. The distance between those two scenarios is the operational gap this response is currently racing to close.

WHO has reported that some health zones in Ituri Province have already achieved 70–100% contact tracing rates. That is genuinely important evidence: it demonstrates that the 70% isolation threshold is operationally achievable in the actual geographic and social context of eastern DRC, with the human resources currently available. The problem is that this reflects the performance of specific high-functioning zones, not the average across all 26 infected health zones, many of which include conflict-affected areas where healthcare workers cannot safely operate. What some zones can do and what all zones are doing are separated by a logistical and security gap that determines everything in the short term. The 736 patients currently in isolation represent a baseline of functioning infrastructure; whether that baseline scales fast enough is the operative question.

The single most urgent short-term variable is South Sudan. The Lancet Infectious Diseases probabilistic spillover model places the 12-week importation probability at 69.3%, and South Sudan's health system — devastated by decades of civil conflict — lacks the institutional capacity to mount even a baseline contact tracing operation from scratch during an active outbreak. Ugandan spillover has already materialized at 20 confirmed cases and 2 deaths. A French export case has been confirmed, and a U.S. citizen humanitarian worker who tested positive on July 10 was medically evacuated to Germany three days later. The question is no longer whether Bundibugyo will cross international borders. It is whether secondary transmission chains will establish themselves in receiving countries and, critically, whether South Sudan can contain an imported case before it seeds a parallel outbreak.

On the vaccine front, the short-term picture is more constrained than public announcements suggest. Oxford's ChAdOx1 candidate can realistically begin manufacturing scale-up within two to three months, given that it uses the same adenovirus vector platform as AstraZeneca's COVID-19 vaccine and the manufacturing processes are already established. But no human safety data exists for this specific Bundibugyo construct. The COVID-19 precedent for emergency use authorization is real, but the political and social context is different: COVID-19 created overwhelming global pressure for compressed regulatory timelines, while Bundibugyo remains concentrated in DRC and Uganda. My realistic expectation is that ChAdOx1 could enter a limited emergency use scenario in Q4 2026, with Q1 2027 as the more probable timeline.

Turning to the medium-term view — six months to two years — the pivotal questions are whether IAVI's rVSV candidate can clear human safety trials and whether the Lancet's base-case scenario of approximately 8,210 cumulative cases by September 2026 holds. The researchers behind the Lancet model have assessed that the recent case trajectory appears closer to the median-to-lower range than to the worst-case projection, which is the best available piece of relative good news in an otherwise grim picture. IAVI's rVSV platform showed 100% non-human primate protection, with CEPI committing up to $3.2 million. But clinical material procurement alone takes 7–9 months, meaning the earliest realistic field deployment is late 2027. The Moderna mRNA candidate, with the single largest CEPI Bundibugyo investment at $50 million, remains in preclinical development. The most optimistic realistic medium-term expectation is that at least one candidate reaches limited emergency deployment in the second half of 2027.

The therapeutic pipeline is even further from the field. Mapp Biopharmaceutical's MBP134 aims to be a pan-ebolavirus monoclonal antibody cocktail that would address multiple species simultaneously. In vitro data suggests that maftivimab — a component of Inmazeb — may retain activity against Bundibugyo, and combinations of remdesivir with monoclonal antibodies are under evaluation. The translation time from in vitro activity to validated human clinical efficacy is typically measured in years, not months, and a realistic expectation for a Bundibugyo-specific therapeutic with clinical validation is 2027–2028 in the most optimistic scenario. Between now and then, thousands of people will face a 30–50% case fatality rate with no pharmacological option. The $270 million committed by the U.S. State Department will have meaningful impact only if a substantial portion reaches field diagnostic and isolation infrastructure rather than concentrating entirely in upstream development pipelines.

For the long-term view of two to five years, I want to lay out three scenarios with analytical honesty about what I consider probable. In the optimistic scenario, at least one CEPI candidate receives regulatory approval and WHO prequalification between 2027 and 2028. A pan-ebolavirus vaccine strategy covering multiple species is actively developed. The outbreak ends in late 2026 or early 2027 with total cases in the 5,000–8,000 range. South Sudan spillover occurs but is contained early through sustained international operational support. This scenario requires isolation rates to reach 70% or higher across all affected health zones and for international field operational capacity to dramatically increase.

In the base-case scenario — which I consider the most probable trajectory — the outbreak extends into early 2027, accumulating 8,000–15,000 total cases. Sporadic cross-border spillover to South Sudan and neighboring countries occurs but does not produce large-scale secondary outbreaks. At least one vaccine candidate enters emergency use during 2027, but mass vaccination campaigns require additional months. The outbreak eventually ends through a combination of intensified non-pharmacological control and early vaccine access, but not before substantial additional mortality.

The pessimistic scenario is the one I find genuinely disturbing when I think through the specific mechanisms that would produce it. If isolation rates remain near the current 20% level — driven by persistent armed conflict blocking healthcare access to transmission hotspots — the Lancet's worst-case projection of 66,000+ cases becomes a live probability. Spillover to South Sudan at scale, followed by cascading spread into Central African Republic and other infrastructure-depleted neighbors, would test whether the international community has genuinely absorbed the lessons it claimed to learn from 2014–2016. That West Africa outbreak also began with early reassurances that the situation was under control. The virus spread because of response delays and resource shortfalls, not because of inherent biological inevitability. The same dynamics are present and active today.

The deepest long-term question is structural: will this outbreak change the R&D incentive problem that created the Bundibugyo gap? I am skeptical but not without hope. The Lancet's framing of this PHEIC as "a turning point for solidarity and health equity" is aspirational language, and aspirational language has historically not translated into the $400 million annual neglected tropical disease R&D funding shortfall getting closed. What would actually close that gap requires binding commitments in whatever pandemic treaty framework emerges from ongoing WHO negotiations, mandatory pathogen-platform licensing for rare but high-consequence pathogens, and advance market commitment mechanisms for pathogens that clear an epidemiological risk threshold even when they lack commercial viability. If the pandemic treaty being negotiated by member states focuses primarily on the next COVID-19 and fails to account for the next Bundibugyo, it will be institutionally obsolete before it is ratified. That is the generational lesson that 719 deaths — and counting — are writing in the clearest possible terms.